chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Headache; Tiredness; sharp excruciating pain in her lower back when she stood up and walked; This is a spontaneous report from a contactable consumer (patient).   A 78-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot Number: EN(6)200), via an unspecified route of administration, administered in left arm on 21Feb2021 as single dose and first dose via an unspecified route of administration, administered in left arm on 31Jan2021 (Lot Number: EN5318) (at the age of 78-year-old) as single dose for COVID-19 immunization. The patient's medical history included pleurisy and bacterial pneumonia, had abdominal surgery and liver hemangioma (maybe 8-10 years ago). The patient's concomitant medication included vitamins NOS. No prior vaccinations within 4 weeks. The patient previously took morphine and experienced severe facial itch, codeine and experienced rapid heart beat and legs very weak. On an unspecified date in Feb2021, the patient experienced sharp excruciating pain in her lower back when she stood up and walked. The patient stated that the patient had the exact same pain when she was treated for bacterial pneumonia a year ago. She suspects it has something to do with the nerve. She wanted to know if this adverse event was reported as an adverse event associated with the vaccine. On 22Feb2021, The patient experienced headache and tiredness. No visits of emergency room and physician office. On 03Feb2021, the patient underwent lab tests and procedures which included MRI: unknown results. On 22Feb2021, the patient recovered from all the events.  No follow-up attempts are possible. No further information is expected.
Low Grade Fever, Chills, Achyiness from the waist down, mild nausea, weakness and sleeplessness for the first 4 days and then diarrhea, fatigue and light headedness for 3 days and then fatigue for 7 days. All totaled I was unwell for 2 weeks.
After I got the vaccine around 30 minutes later I started to feel a headache and pain on my face was not to bad and I tought is a normal symptom but the pain and swelling an my face is increasing every day,  even my teeth hurts and I'm taking Gabapentin 100MG 3 times a day.  I am not sure if the vaccine components triggered my Trigeminal Neuralgia  and if it's okay to get the second dose, I will see my Dr. tomorrow 01/05/21
Pt received vaccine 12/12/06. 12/19/06 pt developed pain and tingling of right temple area. 12/23/06 pt developed blister type rash to temple area and placed on Valtrex. 12/27/06 pt reports pain better, no new blisters.
This spontaneous report as received from a non medical healthcare worker refers to three unspecified patients of unknown age and gender. No information regarding the patients' pertinent medical history, concurrent conditions and concomitant medications was reported. On an unknown date in March 2015, the patients were vaccinated with improperly stored doses of VARIVAX (Merck), lot # K009759, expiration date: 09-JUL-2016, (dose, route and injection site were not reported). No adverse events were reported. Follow up information has been received on 25-MAY-2015 from the reporting non medical healthcare worker. The reporter provided patient identifiers. It was stated that the patient was vaccinated with improperly stored VARIVAX (Merck) on 14-APR-2015 (previously reported as in March 2015). This is one of several reports received from the same reporter. Additional information has been requested. Patient details, suspect therapy details, event details and narrative were updated.
A red blotchy rash covered the injection site and about 8 inches around; no itchiness or other symptoms. Came 1/19 PM and stayed for 24 hours, then disappeared. Arm was extremely sore for the first week after injection, beginning on 1/13/21.
This spontaneous report was received from a pharmacist refers to an 84 year old female patient. Patient's pertinent medical history and drug reactions/allergies were not reported. The patient was not pregnant. On 06-JUN-2015 the patient was vaccinated with PNEUMOVAX 23 (.5 ml, unspecified frequency, lot # K009105, expiry date: 21-JAN-2016). Concomitant medications were not reported. Reporting pharmacist stated that the patient experienced redness, swelling, irritation and tenderness at the injection site after being vaccinated with PNEUMOVAX 23. No treatment was provided for the adverse events. Outcome of all the events was reported as recovering. Causality assessment was not provided. This is one of the three reports received from the same source (MARRS # 1506USA005494 and MARRS # 1506USA005495). Additional information has been requested.
Nerve pain with no history; Unexplained bruising; Circulation Problem/swelling; Circulation Problem/swelling; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 37-year-old female patient received BNT162b2 (BNT162B2), on 09Apr2021 at 15:00 as dose 1, single (Lot number: ER8729) at the age of 37 years intramuscular for covid-19 immunisation. The patient's relevant medical history included: "Pain" (unspecified if ongoing); "Inflammation" (unspecified if ongoing); "Nerve pain" (unspecified if ongoing); "Anxiety" (unspecified if ongoing). Concomitant medication(s) included: MOTRIN [IBUPROFEN] taken for pain, inflammation, start date: Apr2021 (ongoing); CYMBALTA taken for neuralgia, start date: Apr2021 (ongoing); LORAZEPAM taken for anxiety, start date: Apr2021 (ongoing); PREDNISONE taken for inflammation, start date: Feb2022, stop date: Mar2022. The following information was reported: PERIPHERAL VASCULAR DISORDER (non-serious), SWELLING (non-serious) all with onset Apr2021, outcome "unknown" and all described as "Circulation Problem/swelling"; NEURALGIA (non-serious) with onset Apr2021, outcome "unknown", described as "Nerve pain with no history"; CONTUSION (non-serious) with onset Apr2021, outcome "unknown", described as "Unexplained bruising". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Patient took second dose (EW0172) on 30Apr2021 at 15:00 at hospital via an intramuscular route of administration. Patient took third dose (FM0698) on 28Feb2022at 15:00 at hospital via an intramuscular route of administration. Patient took booster dose due to high risk of frequent institutional or occupational exposure to coronavirus (and at risk of serious COVID-19 complications). Patient did not receive any other vaccines within 4 weeks prior to covid vaccine. Patient took first dose and medical issues began.
Myalgia chills, fatigue, loss of appetite Narrative:  Per nursing report: "had 2nd dose of Moderna Wednesday, April 21st [sic]. C/o severe exhaustion, myalgia, chills, no appetite. States feels very tired and fatigued."
Severe incapacitating flare up of pre-existing osteoarthritis (hips, thumbs and both shoulder joints), on day 60 after vaccination. No fever.  Was treated with Vioxx and improved.
So I received vaccine on 2/15. On 2/6 that morning. I awoke with a sore arm. I didn't think it was a big deal. Even though with the first two I didn't even have that. By mid afternoon before boarding my plane. My arm was heavy and the site burned. I had heard about this from others so again. I was like I will soldier through this. I go to shower. As I am standing in the mirror I notice a lump above my heart. My shoulder /neck crevice area is protruding extremely. My upper arm has small lumps as well. I am petrified. But I wasn't having trouble breathing. Which was my main concern. So I showered and took some ibuprofen. 2 hrs later I took tylenol. I drink a gallon of water daily. So I just started medicating with those around the clock. The next day 2/17 when awoke the lumps were bigger and there was a second one above my heart. Under my armpit as well. My lymph nodes were swollen. I could barely hold a cup. So I called in to work. A coworker informed me that her lymph nodes had reacted the same way. I did not go be seen because honestly what could be done. It was a vaccine given with no antidote even if you do have a reaction. As long as I could breathe and didn't feel restricted. I didn't see the point in going.  It took a week for all of the lumps to go awsy.
pt recvd 2nd dose of vax 24MAY92 & devel a 2x2 cc of induration & erythema @ the inject site;
Day 3 post vaccine (3/10/21)began with tingling of lower lip and full sensation, red rash neck, upper chest,back and thighs.  Seen by PCP  and communicated with my rheumatologist . By next day upper lip felt tingly and full  Dri increased my daily medrol to 8 mg .as throat felt tight . Noted next day mucoid eruptions on  upper lips ,palate. Enlarged  bilateral axillary lymph nodes. Rash dissipated by 3/14/21. Still have tight right throat feeling. Still on 6 mg medrol. Still have left shoulder and clavicular discomfort, intermittent tingling both hands and right leg, muscular weakness and fatigue.
I contracted Covid on 20Apr2022; I contracted Covid on 20Apr2022; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 69-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 04Mar2021 at 12:00 as dose 3 (booster), single (Lot number: EN6198) at the age of 69 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: SUSPECTED COVID-19 (medically significant) with onset 20Apr2022, outcome "unknown", DRUG INEFFECTIVE (medically significant), outcome "unknown" and all described as "I contracted Covid on 20Apr2022". Therapeutic measures were taken as a result of drug ineffective, suspected covid-19..  Clinical course: Patient received COVID treatment as Pfizer Paxlovid on 21Apr2022 to 25Apr2022. The patient was not taking any other medications/products within 2 weeks of starting COVID-19 treatment. The patient previously receive a COVID-19 Vaccine.
After over a month post vaccine developed small papular rashes, varicella-like rashes over ears, chest, back, trunk with some pruritus.
02/02, screaming uncontrollably, 02/02-02/03 lying in bed "comatose,"  02/03-02/06, not eating and throwing up what he did, 02/02-02/05, fever of 103.5, not acting himself. Lost 3/4 lbs in 4 days.
Injection site pain (48+ hours & ongoing), tiredness (24 hrs), headache (24 hrs), muscle pain (30 hrs), joint pain (30 hrs), chills (12 hrs), fever (4-8 hrs), nausea (20 hrs)
Really bad abdominal pain; Nagging headche; A spontaneous report was received from a healthcare professional, who was also a 60-year-old female patient, who received Moderna's COVID-19 Vaccine and experienced nagging headache and really bad abdominal pain.  The patient's medical history was not provided. No concomitant medications were provided.  On 23 Dec 2020, prior to the onset of the events, the patient received her first of two planned doses of mRNA-1273 (Batch number 039k20A) intramuscularly in the right arm for prophylaxis of COVID-19 infection.   On 24 Dec 2020, the patient experienced nagging headache. On 25 Dec 2020, she woke up with really bad abdominal pain. Treatment included bismuth subsalicylate.  Action taken with mRNA-1273 in response to the events was not provided  The outcome of the events nagging headache and really bad abdominal pain was not provided.; Reporter's Comments: This case concerns a 60 year old female patient who experienced events of Abdominal pain and Headache. Abdominal pain occurred 3 days after administration of first of two planned doses of mRNA-1273 (Batch number 039k20A) and Headache occurred 2 days after first of two planned doses of mRNA-1273 (Batch number 039k20A). Very limited information regarding the events has been provided at this time. Based on temporal association between the use of the product and the onset of the events, a causal relationship cannot be excluded.
Admitted for Hypoxia. Treatment includes: oxygen, Remdesivir, and Corticosteroids.
This spontaneous report was received from a female patient of unknown age regarding herself. The medical history, concurrent conditions and concomitant medications were not reported. On an unknown date the patient was vaccinated with ZOSTAVAX for prophylaxis. On an unknown date the patient experienced injection site reaction. The outcome of injection site reaction was unknown. The causality was unknown. Additional information has been requested.
RN had diffuse urticarial rash that appeared 9 hours after receiving Moderna vaccine (1st dose) today.  No wheezing, difficulty breathing or throat discomfort reported.  Lungs were clear. Throat exam was normal.  Code blue was activated. Vitals signs were normal. She was given Benadryl 50 mg PO x 1 & transferred.
This spontaneous report was received from a registered pharmacist via a publicist representative, referring to an unknown number of patients of unspecified age and gender. The patients' medical history, concurrent conditions and concomitant therapies were not reported. On unknown dates, the patients were vaccinated with doses of PNEUMOVAX 23 (strength, dose, route, anatomical location, lot number and expiration date were not provided), for immunization. It was reported that on unknown dates, the patients developed redness from the shoulder to the arm after the vaccinations with PNEUMOVAX 23, which usually resolved within 2-3 days. The pharmacist stated that he was seeing that the erythema occurred more frequently. The current status of any of the affected patients with erythema was unknown. The causal relationship between the event and the PNEUMOVAX 23 was not reported.
4 cm induration/erythema at injection site and swollen painful lymph node in axilla. Differential includes cellulitis which was treated for.
Large amount of swelling at the site. Rash in both hands Red swelling itching. Lips swollen itching
PT c/o tingling/ numbness to mouth and throat. administration of Benadryl PO per standing orders. Pt remained on site 15 min w/o additional complaints. PMH - Pt received 1st dose Moderna on 3/18/2021
approx 10-11PM 14 hrs p/inject, pt began noticing swelling of throat & difficult breathing lasting approx 1 hr reports had to sit up in bed to make breathing easier; poss took DPH;
Lymph nodes under left arm and side of left breast swollen and very painful; Lymph nodes under left arm and side of left breast swollen and very painful; Measles like rash on torso front and back. prickly and itchy.; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 23Feb2021 at 12:30 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. The patients' medical history was reported as no. The patient did not receive any medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9264) via an unspecified route of administration in the left arm on 31Jan2021 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Mar2021, the patient experienced swollen and very painful lymph nodes under left arm and side of left breast and measles like prickly and itchy rash on torso front and back. The clinical outcome of the events swollen and very painful lymph nodes under left arm and side of left breast and measles like prickly and itchy rash on torso front and back was resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Pregnant patient reported received the vaccines on 25Feb2021 and 25March2021; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnant patient reported received the vaccines on 25Feb2021 and 25March2021) in a 23-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014M20A and 047A21A) for COVID-19 vaccination.     The patient's past medical history included Alcohol use (social) on 06-Mar-2021. Concurrent medical conditions included Latex allergy. Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for an unknown indication.   On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on 30-Jan-2021 and the estimated date of delivery was 06-Nov-2021. On 25-Feb-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnant patient reported received the vaccines on 25Feb2021 and 25March2021). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  third week of the pregnancy.  On 25-Mar-2021, MATERNAL EXPOSURE DURING PREGNANCY (Pregnant patient reported received the vaccines on 25Feb2021 and 25March2021) had resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-Mar-2021, Pregnancy test positive: positive positive.
Breakthrough case admission after 3 vaccines Pfizer 2/11/21 Lot# EL9269;  Pfizer 3/1/21 Lot# EN6200;  Pfizer 12/10/21 Lot# FJ1611
Mom brought patient back to clinic from pharmacy on 1st floor, itching, rash, c/o stomach ache - gave 6 ml BENADRYL PO, O2 Sat - 99%, vital signs WNL.
no adverse effects reported; patient was vaccinated with improperly stored MMR II; This spontaneous report has been received from a medical assistant, concerning a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not provided.  On 19-MAR-2019, the patient was vaccinated with improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) (albumin status rHA) one dose, lot # R024906 with expiration date 30-AUG-2020 (frequency, route and anatomical location were not provided) which was reconstituted with sterile diluent (dose, frequency, route, lot number and expiration date were not provided) for prophylaxis. No adverse effects reported.  The temperature and time frame were unknown by reporter. There was previously temperature excursions and digital data logger was involved.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1906USA011469: US-009507513-1907USA010301: US-009507513-1907USA010302: US-009507513-1907USA010303: US-009507513-1907USA010304: US-009507513-1907USA010305: US-009507513-1907USA010306: US-009507513-1907USA010307: US-009507513-1907USA010308: US-009507513-1907USA010309: US-009507513-1907USA010310: US-009507513-1907USA010311: US-009507513-1907USA010312: US-009507513-1907USA010313: US-009507513-1907USA010314: US-009507513-1907USA010315: US-009507513-1907USA010316: US-009507513-1907USA010317: US-009507513-1907USA010318: US-009507513-1907USA010319: US-009507513-1907USA010320: US-009507513-1907USA010321: US-009507513-1907USA010322: US-009507513-1907USA010323: US-009507513-1907USA010324: US-009507513-1907USA010325: US-009507513-1907USA010326: US-009507513-1907USA010327: US-009507513-1907USA010328: US-009507513-1907USA010329: US-009507513-1907USA010330: US-009507513-1907USA010331: US-009507513-1907USA010332: US-009507513-1907USA010333: US-009507513-1907USA010334: US-009507513-1907USA010335: US-009507513-1907USA010336: US-009507513-1907USA010337: US-009507513-1907USA010338: US-009507513-1907USA010339: US-009507513-1907USA010340: US-009507513-1907USA010341: US-009507513-1907USA010342: US-009507513-1907USA010343: US-009507513-1907USA010344: US-009507513-1907USA010345: US-009507513-1907USA010346: US-009507513-1907USA010347: US-009507513-1907USA010348: US-009507513-1907USA010349: US-009507513-1907USA010350: US-009507513-1907USA010351: US-009507513-1907USA010352: US-009507513-1907USA010353: US-009507513-1907USA010355: US-009507513-1907USA010356: US-009507513-1907USA010357: US-009507513-1907USA010358: US-009507513-1907USA010359: US-009507513-1907USA010360: US-009507513-1907USA010361: US-009507513-1907USA010362: US-009507513-1907USA010363: US-009507513-1907USA010364: US-009507513-1907USA010365: US-009507513-1907USA010366: US-009507513-1907USA010367: US-009507513-1907USA010368: US-009507513-1907USA010369: US-009507513-1907USA010370: US-009507513-1907USA010371: US-009507513-1907USA010372: US-009507513-1907USA010373:
Patient complained of feeling lightheaded 5 minutes after receiving TdAp vaccine.Patient then fainted and had a loss of consiousness for 15 seconds. Patient alert and oriented and easily aroused after 15 seconds. Patient was asssited back into exam room and while sitting in the chair, fainted with a loss of consiousness for 10 seconds.  Paitent remained breathing throughout the incident.Patient placed on exam table in supine position.  Blood pressure 100/50, skin very plale and diaphoretic. EMS called and patient taken to Emergency Department.
PATIENT FAINTED AND STARTED SEIZING ABOUT 2 MINUTES AFTER RECEIVING HER FLUCELVAX IMMUNIZATION.  SHE SEIZED FOR ABOUT 15 SECONDS.  ONCE THE SEIZURE STOPPED, SHE TOLD ME THAT SHE USUALLY FAINTS AND SEIZES WHEN SHE GETS A SHOT BECAUSE SHE IS SO NERVOUS.  AMBULANCE WAS CALLED.  PATIENT REFUSED CARE.
The correct diluent was not used to mix the vaccine before administration. Unsteady of 1.8 ml, only 0.8 ml was drawn and was used to dilute the vaccine. Patient received the immunization without complication during administration. Patient was contacted on 12/8 for follow up and patient denied having any complications after receiving the vaccine. Patient verbalized feeling good and declined any side effect
This is a spontaneous report received from a contactable other HCP. A male patient received unknown dose number of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine, batch/lot# unknown), single dose, for COVID-19 immunisation. Medical history and concomitant medications not reported. The patient experienced lymphadenopathy (husband had a swollen lymph node in his hand after receiving the vaccine), with outcome of unknown. Additional information: HCP stated she received the 1st dose of the Pfizer COVID-19 vaccine about 2 ½ weeks ago. She experienced swollen lymph nodes, which lasted more than 2 weeks. Her neck was swollen and tight. She couldn't walk. Her husband had a swollen lymph node in his hand after receiving the vaccine. She had to sit after getting the dose. She has an allergy to sulfites. Her heart rate went faster and felt like a rush of blood to head. She had a period (menstrual cycle) twice; and it's been lasting longer than usual. She asked for a letter stating she shouldn't get the 2nd dose. Follow-up attempts completed. No further information expected.
DIAGNOSIS OF COVID-19 WITH HOSPITALIZATION/DEATH AFTER BEING FULLY VACCINATED
24 hours after injection, erythema, some induration by 72 hours, had reddened 10cm diameter. Minimal tenderness, slight itchy.
9 pt recv vax & 7 had no detectable humoral response, while the remaining two pt produced low titers (1.2 and 1.8);2 pt over age 13 both had low titers (1.2 and 1.8);
This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. Concurrent conditions, medical history and allergies were not reported. On 28-MAY-2015, the patient was vaccinated with one dose of M-M-R II, (strength, dose, frequency, route and anatomical location were not reported) (lot # J008153 with expiration date: 08-JUL-2015), which was improperly stored. No adverse effects were reported. Additional information has been requested.